Seres Starts Academic Partnerships to Test Microbiome Therapies for Inflammatory Bowel Disease

Seres Starts Academic Partnerships to Test Microbiome Therapies for Inflammatory Bowel Disease
Seres Therapeutics, Inc., announced the initiation of two academic research collaborations  to further develop the company’s microbiome therapeutics platform as a treatment for inflammatory bowel disease (IBD). Under the agreements, the company will work with teams at the Research Institute of St. Joseph’s Hamilton, Canada, and the Medical University of Graz, Austria. Seres’ drug pipeline includes SER-287, the first microbiome therapeutic candidate to reach clinical-stage development in a chronic disease.  Developed and manufactured as an oral capsule, SER-287 is 
Subscribe or to access all post and page content.